Stephanie Davis
Stock Analyst at Barclays
(1.26)
# 3,486
Out of 4,876 analysts
95
Total ratings
36.92%
Success rate
-13.3%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $175 → $185 | $177.83 | +4.03% | 5 | Apr 23, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $39.76 | +13.18% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $13.64 | -63.34% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $61.09 | +22.77% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $5.14 | +36.19% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.90 | +22.45% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $11.16 | +70.25% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $299.42 | -3.15% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $21.58 | +11.21% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $167.18 | -20.45% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $29.38 | +97.41% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $2.77 | +8.30% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $260.59 | -4.45% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $28.44 | +1.97% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $8.41 | +304.28% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $21.89 | +55.32% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $283.41 | -17.79% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $3.81 | +346.19% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $104.88 | -27.54% | 5 | Jun 7, 2022 |
Quest Diagnostics
Apr 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $185
Current: $177.83
Upside: +4.03%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $39.76
Upside: +13.18%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $13.64
Upside: -63.34%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $61.09
Upside: +22.77%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $5.14
Upside: +36.19%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.90
Upside: +22.45%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $11.16
Upside: +70.25%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $299.42
Upside: -3.15%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $21.58
Upside: +11.21%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $167.18
Upside: -20.45%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $29.38
Upside: +97.41%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.77
Upside: +8.30%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $260.59
Upside: -4.45%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $28.44
Upside: +1.97%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $8.41
Upside: +304.28%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $21.89
Upside: +55.32%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $283.41
Upside: -17.79%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $3.81
Upside: +346.19%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $104.88
Upside: -27.54%